# Study of Standard and Individualized Treatment Model for Relapse and Refractory Lymphatic System Malignant Tumors

> **NCT02929615** · PHASE4 · UNKNOWN · sponsor: **Peking University** · enrollment: 50 (estimated)

## Conditions studied

- Lymphoma

## Interventions

- **OTHER:** Hematopoietic stem cell transplantation

## Key facts

- **NCT ID:** NCT02929615
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-06
- **Primary completion:** 2017-12
- **Final completion:** 2018-03
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2016-10-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02929615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02929615, "Study of Standard and Individualized Treatment Model for Relapse and Refractory Lymphatic System Malignant Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02929615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*